NicVAX

NicVAX is a vaccine that was developed by Nabi Biopharmaceuticals to help in the treatment of nicotine addiction. It works by stimulating the immune system to produce antibodies that bind to nicotine, preventing it from reaching the brain and thereby reducing the pleasurable effects of smoking and helping individuals to quit.

History

NicVAX was developed by Nabi Biopharmaceuticals, a company that specializes in the development of vaccines for infectious diseases and other disorders. The vaccine was first announced in 2005, and it entered Phase III clinical trials in 2007. However, in 2011, the company announced that the vaccine had failed to meet its primary endpoint in these trials, and development was subsequently discontinued.

Mechanism of action

The active ingredient in NicVAX is a hapten called 3'-aminomethylnicotine, which is chemically similar to nicotine. When this hapten is injected into the body, it stimulates the immune system to produce antibodies that recognize and bind to nicotine. Once these antibodies are present in the bloodstream, they can bind to nicotine molecules that enter the body when a person smokes a cigarette. This prevents the nicotine from reaching the brain, where it would normally bind to nicotinic acetylcholine receptors and trigger the release of dopamine, a neurotransmitter that is associated with feelings of pleasure and reward. By blocking the effects of nicotine in this way, NicVAX helps to reduce the desire to smoke and makes it easier for individuals to quit.

Clinical trials

NicVAX underwent a series of clinical trials to assess its safety and efficacy. The Phase I and II trials, which were conducted between 2005 and 2007, showed that the vaccine was safe and well-tolerated, and that it could stimulate the production of anti-nicotine antibodies. However, the Phase III trials, which were conducted between 2007 and 2011, failed to show a significant difference in quit rates between individuals who received the vaccine and those who received a placebo. As a result, development of the vaccine was discontinued.

See also

• Smoking cessation
• Nicotine replacement therapy
• Vaccine

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia